Blocking P2X7 Receptor Reduces Neuroinflammation in Human Brain Tissue
University of Birmingham scientists have demonstrated that blocking the P2X7 receptor significantly reduces inflammatory responses in living human brain tissue, offering a new therapeutic strategy for conditions like traumatic brain injury, Alzheimer's, Parkinson's, and depression.
Blocking the P2X7 receptor significantly reduced inflammation in human brain tissue. This finding offers a new potential treatment strategy for neuroinflammatory conditions like Alzheimer’s, Parkinson’s, depression, and schizophrenia. The research used live cultures of human brain cells and slices of brain tissue obtained during neurosurgery. A specific antagonist was used to block the P2X7 receptor, which is a driver of neuroinflammation. This receptor promotes the release of cytokines involved in inflammatory signaling. The antagonist interfered with signals from microglia, the brain's resident immune cells, as they became damaged and died. The anti-inflammatory effect was validated in living human brain tissue slices. The P2X7 receptor acts as a primary trigger for inflammatory signaling in the central nervous system. It is activated by extracellular ATP released by injured or dying cells. Blocking it stops the release of pro-inflammatory cytokines like IL-1β and IL-18 in a concentration-dependent manner. The discovery provides a direct, accelerated bridge to clinical trials for traumatic brain injury, Alzheimer’s, Parkinson’s, and severe depression.
Innovative model overcomes microglia study limitations
Studying human microglia has long been a major challenge. Once removed from their native brain environment, they rapidly lose their defining characteristics. The research team overcame this by developing a method to create microglia-like cells from human peripheral blood monocytes. This provides a powerful, scalable platform for studying human microglial biology with unprecedented precision. Having identified the response in these monocyte-derived microglia, the team translated the findings to human brain tissue obtained from neurosurgical resections. Professor Nicholas Barnes, the study's corresponding author, explained the significance. "Studying human microglia has long been a major challenge: once removed from their native brain environment, they rapidly lose their defining characteristics," he said.
Implications for TBI and neurodegenerative diseases
The findings support potential clinical trials for a range of conditions where treatments are limited. Neuroinflammation is a shared driver across traumatic brain injury, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, major depressive disorder, and schizophrenia. Traumatic brain injury is a major cause of death globally, yet there are no approved therapeutic drugs to improve clinical outcomes. Conditions including depression, psychosis, and schizophrenia are now being understood to have a neuroinflammatory component. The successful demonstration of the mechanism in human brain tissue provides a foundation for further development. Existing P2X7 antagonist drugs have already undergone clinical testing. Repurposing them bypasses the standard safety and toxicology delays that can slow novel drug development by 10 to 15 years.
Expert commentary on translation to patients
Professor Nicholas Barnes, a Professor of Neuropharmacology at the University of Birmingham, emphasized the translational potential. "This exciting discovery marks a major step toward repurposing existing therapeutics to combat neuroinflammation at its source," he stated. He noted that the next stage is the development of clinical trials in patients with neurodegenerative conditions and patients with TBI. These are areas where there are no effective pharmacological treatments to reduce the neuroinflammation and arising damage. The research team is organizing clinical trial protocols for patients with neurodegenerative conditions and TBI.
